Samples from post-mortem patients and mouse models consistently reveal elevated levels of PERK, p-PERK, and p-eIF2α in various neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease, and Huntington’s disease. This evidence concerns the gene EIF2A and Alzheimer disease.